New research found that the Moderna COVID-19 vaccine, which was recently shown to be 94 percent effective, induces the human immune system to develop strong antibodies that last for at least three months, according to a report from MedicalXpress.
The National Institute for Allergies and Infectious Diseases (NIAID), who examined the immune responses of 34 participants, claimed in the New England Journal of Medicine that the antibodies preventing the invasion of human cells by the SARS-CoV-2 virus "declined slightly over time." But the level remained high in all participants 3 months after the booster vaccination."
It says the antibodies that the shot creates only last three months after administration to protect the coronavirus. It adds that the antibodies decreased significantly over time but also stayed three months after vaccination in all the participants. However, it claims the situation is not a cause of concern.
NIAID director Anthony Fauci and other professionals in infectious diseases suggest it is possible for our bodies to recall the infection and once subjected to the virus again to generate more antibodies. As per the report, a certain form of immune cell was also produced by Moderna's vaccine, which could aid in the memory response against COVID19. To authenticate the argument, however, further studies are required, it said.
Meanwhile, Moderna has submitted to the US Food and Drug Administration (FDA) for an emergency vaccine approval and will be reviewed on December 17. Moderna's mRNA-1273 vaccine is focusing on the newest and innovative mRNA strategy and is given after 28 days in two doses.
In cooperation with the National Institute of Allergy and Infectious Diseases (NIAID), member of the National Institutes of Health (NIH), and the Biomedical Advanced Science and Development Authority, Moderna's COVID-19 studies, also known as the COVE analysis, enrolled more than 30,000 participants in the US (BARDA).
Moderna has previously said in a separate announcement that its COVID-19 vaccine candidate remained stable at 2-degree Celsius to 8-degree Celsius, the temperature of a regular home or medical refrigerator for 30 days. It also reported that mRNA-1273 remained stable for up to six months at -200 C (-40F), up to 30 days in refrigerated environments, and up to 12 hours at room temperature.
CAMBRIDGE, MASSACHUSETTS - MAY 08: A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts. Moderna was given FDA approval to continue to phase 2 of Coronavirus (COVID-19) vaccine trials with 600 participants.
mRNA technique
For the first time, the "messenger RNA" technique would be used if these vaccinations - from Moderna and Pfizer - are approved for mass deployment. Although the technique was introduced in the 1990s, the first to use the mRNA technique to resolve a harmful inflammatory reaction seen in animals was Weissman scientists and colleague Katalin Kariko. In specific, Kariko is now BioNTech's senior vice president and Weissan has worked as an advisor to the organization. BioNTech, a German pharmaceutical firm, produced the vaccine along with Pfizer.
The vaccine guides our cells to grow Covid-19 antibodies or spike proteins utilizing the mRNA technique. Our immune system produces antibodies without being introduced to the infection after seeing these spiked proteins.
This current approach is known to be better but more costly than conventional models, and there is little risk that an individual from COVID-19 would be contaminated with spike proteins. It also grows quicker than typical ones and tends to make immune cells, which further help to create antibodies against the virus.
ALSO READ: Volunteer for Pfizer's Experimental COVID-19 Vaccine Shares Side Effects from Trial
Check out more news and information on COVID-19 on Science Times.
